GLP/GCP | Bioscience Labs

GLP/GCP

BioScience Laboratories Quality Program


BioScience Laboratories, Inc. (BSLI) complies with the tenets of Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), as defined by the U.S. Food and Drug Administration (FDA; 21 CFR Parts 50, 56, 58, 312 and 314), the U.S.  Environmental Protection Agency (EPA; 40 CFR Part 160), and the International Conference on Harmonisation (ICH; Guidlines for Industry E3, E6, E9 and Q4B, inclusive of Annexes 4A, 4B and 4C). The extensive battery of SOPs that BSLI has developed on the basis of these general regulatory guidelines has been examined extensively numerous times by corporate and regulatory auditors and found to assure adherence to the tenets of GLP and GCP. 
 


Good Laboratory Practice GLP Testing Services

BioScience Laboratories, Inc. maintains a Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) quality program that ensures our clients' studies are performed well and in compliance with regulatory requirements. Each study undergoes a quality review prior to initiation, in-process audits, and a final quality audit upon completion. A continuous quality improvement process is in place to address any discrepancies and consistently enhance the value of our services.

Our GLP Laboratories are in good standing with the United States Food and Drug Administration (FDA) and the United States Environmental Protection Agency (EPA).  As such, we follow GCP and GLP Regulations.
 


What our Customers are Saying...

"There was absolutely no comparison between the kind of service and expertise I obtained from BioScience compared to the competition. It was obvious I had to place studies with BioScience Laboratories." 

Joel Ivers, Union Springs Pharmaceuticals.

I have enjoyed a good relationship with BioScience Laboratories.  Thanks to their support and thought-provoking advice, we were able to move forward on several of our projects.  I look forward to continuing a business relationship with BioScience Laboratories for years to come.”

Yutaka Nishihara, Ph.D., Yoshida Pharmaceutical Co., Ltd.